Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients

ConclusionsROMO continuously increased BMD for 12  months and performed better than DENO. On the other hand, effects of ROMO switched from BP on BMD of femoral neck and total hip were almost same with DENO. Bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months may predict the efficacy of ROMO after 12 months of adm inistration.
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research